United States   Tech   Markets   Politics   Business   Science   Memes  









New-data-shows-immunotherapy-drug-durvalumab-is-well-tolerated-and-may-improve-survival-in-lung-cancer-patients-with-limited-physical-function 




Sort By:                     

✅   Cost-effectiveness of consolidation durvalumab for inoperable stage III non-small cell lung cancer in Vietnam

Health

Background This study aimed to assess the cost-effectiveness of durvalumab as a treatment option for patients with inoperable stage III non-small cell lung cancer (NSCLC) from healthcare and partial societal perspectives in Vietnam. Method A lifetime partitioned survival model was used to evaluate the costs and quality-adjusted life years (QALYs) associated with consolidation durvalumab in comparison with the standard of care alone. Local costs and utilities were incorporated into the model. In the base-case analysis, no discount was applied to the acquisition cost of durvalumab. Scenario-based, one-way and probabilistic-sensitivity analyses were conducted. Results The base-case analysis revealed that the intervention resulted in an increase of 1.38 life years or 1.08 QALYs for patients, but the ...

BMJ     Aug 30, 2024